| [1] |
Torre LA, Bray F, Siegel RL , et al. Global cancer statistics, 2012[J]. CA: a cancer journal for clinicians, 2015,65(2):87-108.
|
| [2] |
Engstrand J, Nilsson H, Strömberg C , et al. Colorectal cancer liver metastases - a population-based study on incidence, management and survival[J]. BMC cancer, 2018,18(1):78.
|
| [3] |
葛大壮, 赵建军, 黄振, 毕新宇, 蔡建强 . MDT指导下多程治疗直肠癌肝转移临床治愈一例[J]. 肝癌电子杂志, 2019,6(03):24-27.
|
| [4] |
B Section of Gastrointestinal Surgery CMA, B Section of Colorectal & Anal Surgery, Chinese Medical Association; A CoCCoCA-C;, CCoS Chinese Society of Colon & Rectal Surgeons, Chinese Medical Doctors Association;, CIEaPAfMaHC Committee of Colorectal Liver Metastases Treatment.: Guideline for the diagnosis and comprehensive treatment of colorectal cancer with liver metastases (2016 edition). Chin J Dig Surg, 2016: 15(18):755-767.
|
| [5] |
ONCOLOGY CSOC. GUIDELINES OF CHINESE SOCIETY OF CLINICAL ONCOLOGY (CSCO) COLORECTAL CANCER[J]. People's Medical Publishing House, 2019.
|
| [6] |
Network NCC . NCCN clinical practice guidelines in Oncology:Rectal Cancer(2019.V2)[J]. 2019.
|
| [7] |
Beppu T, Miyamoto Y, Sakamoto Y, et al. Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival[J]. Annals of surgical oncology, 2014,21 Suppl 3: S405-413.
|
| [8] |
Hubert C, Lucidi V, Weerts J , et al. Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): Multicentric study of patients operated for colorectal liver metastases[J]. European journal of surgical oncology, 2018,44(10):1532-1538.
|
| [9] |
Vigano L, Capussotti L, De Rosa G, et al. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival[J]. Annals of surgery, 2013, 258(5): 731-740; discussion 741-732.
|
| [10] |
Zhao J, van Mierlo KMC, Gomez-Ramirez J , et al. Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases[J]. The British journal of surgery, 2017,104(8):990-1002.
|
| [11] |
Adam R, Bhangui P, Poston G , et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases[J] ? Annals of surgery, 2010,252(5):774-787.
|
| [12] |
Konopke R, Kersting S, Distler M , et al. Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases[J]. Liver international, 2009,29(1):89-102.
|
| [13] |
Minagawa M, Yamamoto J, Kosuge T, et al. Simplified staging system for predicting the prognosis of patients with resectable liver metastasis: development and validation[J]. Archives of surgery, 2007, 142(3): 269-276; discussion 277.
|
| [14] |
Nagashima I, Takada T, Matsuda K , et al. A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection[J]. Journal of hepato-biliary-pancreatic surgery, 2004,11(2):79-83.
|
| [15] |
Fong Y, Fortner J, Sun RL , et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases[J]. Annals of surgery, 1999, 230(3): 309-318; discussion 318-321.
|
| [16] |
Ayez N, van der Stok EP, Grunhagen DJ , et al. The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator[J]. European journal of surgical oncology, 2015,41(7):859-867.
|
| [17] |
Zhu D, Zhong Y, Wei Y , et al. Effect of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases[J]. PloS one, 2014,9(1):e86543.
|
| [18] |
Liu W, Zhou JG, Sun Y , et al. The role of neoadjuvant chemotherapy for resectable colorectal liver metastases: a systematic review and meta-analysis[J]. Oncotarget, 2016,7(24):37277-37287.
|
| [19] |
Van Cutsem E, Cervantes A, Adam R , et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer[J]. Annals of oncology, 2016,27(8):1386-1422.
|
| [20] |
Sabanathan D, Eslick GD, Shannon J . et al. Use of Neoadjuvant Chemotherapy Plus Molecular Targeted Therapy in Colorectal Liver Metastases: A Systematic Review and Meta-analysis[J]. Clinical colorectal cancer, 2016,15(4):e141-e147.
|
| [21] |
Primrose J, Falk S, Finch-Jones M , et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial[J]. The Lancet Oncology, 2014,15(6):601-611.
|
| [22] |
Hurwitz H, Fehrenbacher L, Novotny W , et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. The New England journal of medicine, 2004,350(23):2335-2342.
|
| [23] |
Lim C, Doussot A, Osseis M , et al. Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first[J]. Clinical & translational oncology, 2018,20(10):1274-1279.
|
| [24] |
Rong Z, Martel G, Vandenbroucke-Menu F , et al. Impact of peri-operative bevacizumab on survival in patients with resected colorectal liver metastases: an analysis of the LiverMetSurvey[J]. HPB, 2014,16(4):342-349.
|
| [25] |
Ranpura V, Hapani S, Wu S , et al. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis[J]. JAMA, 2011,305(5):487-494.
|
| [26] |
Rubbia-Brandt L, Giostra E, Brezault C , et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery[J]. Annals of oncology, 2007,18(2):299-304.
|
| [27] |
Serayssol C, Maulat C, Breibach F , et al. Predictive factors of histological response of colorectal liver metastases after neoadjuvant chemotherapy[J]. World journal of gastrointestinal oncology, 2019,11(4):295-309.
|
| [28] |
Blazer DG, Kishi Y, Maru DM , et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases[J]. Journal of clinical oncology, 2008,26(33):5344-5351.
|
| [29] |
Mao R, Zhao JJ, Bi XY , et al. A Low Neutrophil to Lymphocyte Ratio Before Preoperative Chemotherapy Predicts Good Outcomes After the Resection of Colorectal Liver Metastases[J]. Journal of gastrointestinal surgery, 2019,23(3):563-570.
|
| [30] |
Shaikh T, Ruth K, Scott WJ , et al. Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer[J]. The Annals of thoracic surgery, 2015,99(1):270-276.
|
| [31] |
Ruol A, Rizzetto C, Castoro C , et al. Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: does delayed surgery have an impact on outcome? [J] Annals of surgery, 2010,252(5):788-796.
|
| [32] |
Liu Y, Zhang KC, Huang XH , et al. Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes[J]. World Journal of gastroenterology, 2018,24(2):257-265.
|
| [33] |
Lin G, Han SY, Xu YP , et al. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies[J]. Diseases of the esophagus, 2016,29(8):1107-1114.
|
